Evidence map›Paper›PMID 32635553›Full record

ArticleAntibiotics (Basel, Switzerland)2020

Impact of Case Definitions on Efficacy Estimation in Clinical Trials-A Proof-of-Principle Based on Historical Examples.

Andreas Hahn, Hagen Frickmann, Andreas E Zautner

Abstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Antimicrobial Resistance Patterns inAntibiotics (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Andreas HahnInstitute for Medical Microbiology, Virology and Hygiene, University Medicine Rostock, 18057 Rostock, Germany.
Hagen FrickmannInstitute for Medical Microbiology, Virology and Hygiene, University Medicine Rostock, 18057 Rostock, Germany.
Andreas E ZautnerInstitut für Medizinische Mikrobiologie, Universitätsmedizin Göttingen, 37075 Göttingen, Germany.

Funding

Deutsche Forschungsgemeinschaft DFG ZA 697/6-1Forschungsförderungsprogramm of the Universitätsmedizin Göttingen (UMG), Germany not applicableOpen Access Support Program of the Deutsche Forschungsgemeinschaft not applicablepublication fund of the Georg-August-Universität Göttingen not applicable
6 · The paper itself

Abstract

Efficacy estimations in clinical trials are based on case definitions. Commonly, they are a more or less complex set of conditions that have to be fulfilled in order to define a clinical case. In the simplest variant, such a case is identical with a single positive diagnostic test result. Frequently, however, case definitions are more complex. Further, their conditions often ignore the inherent logical structure of symptoms and disease: A symptom or a set of symptoms may be necessary but not sufficient for the unambiguous identification of a case. After describing the structure of case definitions and its impact on efficacy estimations, we exemplify this impact using data from two clinical trials dealing with the effectiveness of the vaginal application of tenofovir gel for the prevention of HIV infections and with the therapeutic effects of fecal transplantation on recurrent

Indexed as

case definitionclinical trialefficacy estimationspecificity

Identifiers

PMID32635553
PMCPMC7400704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.